VRTX-531 demonstrates best-in-class USP1 inhibitor activity in preclinical models
Nov. 5, 2024
Researchers from Vrise Therapeutics Inc. and Vegen Therapeutics Pvt Ltd. presented preclinical data for VRTX-531, an allosteric inhibitor of ubiquitin carboxyl-terminal hydrolase 1 (USP1), being developed for the treatment of cancer.